Clinical Trials Logo

Clinical Trial Summary

This study will evaluate the PK, PD and long-term safety of Benralizumab administered subcutaneously in 30 children aged 6 to 11 years with severe eosinophilic asthma. Up to an additional 3 Japanese patients aged 12 to 14 years will be enrolled to meet local regulatory requirements.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04305405
Study type Interventional
Source AstraZeneca
Contact
Status Completed
Phase Phase 3
Start date November 21, 2019
Completion date September 12, 2022

See also
  Status Clinical Trial Phase
Completed NCT04200326 - Real-life First Dose Effect of Fasenra in Patients With Severe Uncontrolled Asthma